News
-
-
-
PRESS RELEASE
Redcare Pharmacy: strong Q3 growth combined with 2% adj. EBITDA margin. Rx momentum in Germany further increased, with sales growth of over 130% in October.
Redcare Pharmacy reports strong Q3 growth with 2% adj. EBITDA margin. Rx sales surge by over 130% in Germany. Total Group sales up 21% in Q3 to EUR 575M -
-
-
-
-
PRESS RELEASE
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics.
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany and 108% in September, leading to accelerated marketing efforts based on strong e-Rx metrics. Full-year 2024 guidance updated for increased marketing activity -
PRESS RELEASE
EQS-Adhoc: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September. Full-year guidance updated with strategic decision to accelerate marketing in Q4 based on convincing e-Rx metrics -
